Exploratory study of interferon regulatory factor 3 promoting proliferation and invasion related to colorectal cancer cells

doi:10.3969/j.issn.1674-8115.2024.03.002

Abstract

Abstract:

Objective ·To analyze the relationship between the expression level of interferon regulatory factor 3 (IRF3) in colorectal cancer and its clinicopathological features and prognosis, and to observe the effects of IRF3 overexpression on the proliferation and invasion ability of colorectal cancer cells and the related protein molecular pathways. Methods The Cancer Genome Atlas (TCGA) data were downloaded and used to analyze the correlation between expression levels of IRF3 and the prognosis of patients (including renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, and prostate cancer). Immunohistochemistry was used to detect the differences in the expression levels of IRF3 between cancerous tissue and adjacent normal tissues of 10 patients with colorectal/renal cancer. The C-terminal residue sites of the IRF3 protein were modified to construct HEK-293T cells overexpressing the phosphorylated IRF3-5D (396/398/402/404/405-D). At 12 and 24 h of cell culture, treatment with TANK-binding kinase 1 (TBK1) inhibitor was performed, and Western blotting was used to detect the expression levels of IRF3 and p-IRF3 (Ser386) in the cells. RNA sequencing (RNA-seq) was employed to explore the correlation between high expression of IRF3-5D and the expression levels of tumor-related proteins. Colorectal cancer cells CT26 and COLON26 overexpressing wild-type IRF3 (IRF3-WT) and IRF3-5D were construct, and cell proliferation and migration ability were assessed by using cell counting, scratch assay, and clonogenic assay. Results ·Analysis of TCGA data suggested that the expression level of IRF3 protein in cancer tissues was positively correlated with poor prognosis in patients. Immunohistochemical analysis of pathological tissues from patients with cancer showed that the expression level of IRF3 was significantly upregulated in colorectal cancer tissues and renal cancer tissues, with protein expression concentrated in the cell nucleus. After treatment with TBK1 inhibitors for 12 and 24 h in cell culture, the expression of p-IRF3 (Ser386) protein in HEK-293T cells decreased. The results of RNA-seq and Western blotting showed that the expression levels of multiple proteins associated with poor prognosis [such as IRF9, programmed cell death 1-ligand 1 (PD-L1), etc.] were significantly upregulated under conditions of high expression of IRF3-5D. Overexpression of IRF3-5D in colorectal cancer cells could significantly enhance the proliferation and migration capabilities of cancer cells. Conclusion ·The expression level of IRF3 in colorectal cancer is positively correlated with poor patient prognosis. High expression of IRF3-5D protein in colorectal cancer cells can promote malignant biological behavior of cancer cells. Additionally, IRF3-5D is dependent on the TBK1-mediated activation of the IRF3 activation pathway and upregulates the expression levels of multiple tumor-related proteins.

Key words: colorectal malignant tumour, targeted therapy, interferon regulatory factor 3 (IRF3), TANK-binding kinase 1 (TBK1), RNA sequencing (RNA-seq)

CLC Number:

R735.3⁺5

XU Wenhui, YANG Chang, LI Ruiqing, BIAN Jing, LI Xiayi, ZHENG Leizhen. Exploratory study of interferon regulatory factor 3 promoting proliferation and invasion related to colorectal cancer cells[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 301-311.

Figures/Tables 10

Fig 1 Kaplan-Meier survival analysis based on different IRF3 expression levelsNote: A. Renal cancer. B. Colorectal cancer. C. Liver cancer. D. Prostate cancer.

Fig 2 Comparison of immunohistochemical staining for IRF3 protein between cancerous and normal tissues adjacent to cancer in patients with colorectal cancer （×20）Note: A. Normal intestinal tissue adjacent to cancer. B. Cancerous tissue.

Fig 3 Comparison of immunohistochemical staining for IRF3 protein between cancerous and normal tissues adjacent to cancer from patients with renal cancer （×20）Note: A. Normal kidney tissue adjacent to cancer. B. Cancerous tissue.

Fig 4 Changes in IRF3 expression with TBK1 inhibitor at different time points

Fig 5 Heat map of differential gene clusterings between the three groups

Fig 6 Gene enrichment analysis graphs of GO（A） and KEGG（B）

Fig 7 Comparison of the results of the four immunoblots

Fig 8 Comparison of growing capacity among three groups of CT26 and COLON26 cell

Fig 9 Comparison of invasive ability among three groups of CT26 cells

Fig 10 Comparison of cell viability among three groups of COLON26 cells

TrendMD

References 39

1	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	周雄, 胡明, 李子帅, 等. 2020年全球及中国结直肠癌流行状况分析[J]. 海军军医大学学报, 2022, 43(12): 1356-1364.
	ZHOU X, HU M, LI Z S, et al. Colorectal cancer in the world and China in 2020: an analysis of epidemic status[J]. Academic Journal of Naval Medical University, 2022, 43(12): 1356-1364.
3	李建, 张尧, 胡登敏, 等. 1990—2019年中国人群早发性结直肠癌疾病负担及变化趋势分析[J]. 现代预防医学, 2022, 49(19): 3468-3473.
	LI J, ZHANG Y, HU D M, et al. Disease burden and its time trends of early-onset colorectal cancer in China, 1990—2019[J]. Modern Preventive Medicine, 2022, 49(19): 3468-3473.
4	ZHOU W K, WANG J M, WANG X, et al. Degradation of HDAC10 by autophagy promotes IRF3-mediated antiviral innate immune responses[J]. Sci Signal, 2022, 15(765): eabo4356.
5	ZHANG Q, LIU S D, ZHANG C S, et al. AMPK directly phosphorylates TBK1 to integrate glucose sensing into innate immunity[J]. Mol Cell, 2022, 82(23): 4519-4536.e7.
6	SUN X C, XIN S Y, LI W Y, et al. Discovery of Notch pathway-related genes for predicting prognosis and tumor microenvironment status in bladder cancer[J]. Front Genet, 2022, 13: 928778.
7	SONG J, ZHAO W, ZHANG X, et al. Mutant RIG-Ⅰ enhances cancer-related inflammation through activation of circRIG-Ⅰ signaling[J]. Nat Commun, 2022, 13: 7096.
8	SHAN S H, NIU J P, YIN R P, et al. Peroxidase from foxtail millet bran exerts anti-colorectal cancer activity via targeting cell-surface GRP78 to inactivate STAT3 pathway[J]. Acta Pharm Sin B, 2022, 12(3): 1254-1270.
9	SAIKRUANG W, ANG YAN PING L, ABE H, et al. The RNA helicase DDX3 promotes IFNB transcription via enhancing IRF-3/p300 holocomplex binding to the IFNB promoter[J]. Sci Rep, 2022, 12(1): 3967.
10	OKAMURA K, NAGAYAMA S, TATE T, et al. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy[J]. J Transl Med, 2022, 20(1): 241.
11	PASCOLUTTI R, YETURU L, PHILIPPIN G, et al. ATP128 clinical therapeutic cancer vaccine activates NF-κB and IRF3 pathways through TLR4 and TLR2 in human monocytes and dendritic cells[J]. Cancers, 2022, 14(20): 5134.
12	LIU J, JI Q L, CHENG F, et al. The lncRNAs involved in regulating the RIG-Ⅰ signaling pathway[J]. Front Cell Infect Microbiol, 2022, 12: 1041682.
13	YANG Y Y, CAO X Y, HUANG L S, et al. RNF19a inhibits antiviral immune response to RNA viruses through degradation of TBK1[J]. Mol Immunol, 2022, 143: 1-6.
14	寻鲁宁, 王冲, 沈成凤, 等. 1990—2019年中国结直肠癌发病趋势分析及预测模型比较[J]. 中国肿瘤, 2023, 32(4): 279-286.
	XUN L N, WANG C, SHEN C F, et al. Prediction of colorectal cancer incidence in China with three different models based on trends from 1990 to 2019[J]. China Cancer, 2023, 32(4): 279-286.
15	FANG X L, XU J F, JIN K T, et al. Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: achievements and limitations[J]. Int Immunopharmacol, 2023, 118: 110062.
16	FANG G D, XU D L, ZHANG T, et al. Biological functions, mechanisms, and clinical significance of circular RNA in colorectal cancer[J]. Front Oncol, 2023, 13: 1138481.
17	UHLÉN M, BJÖRLING E, AGATON C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics[J]. Mol Cell Proteomics, 2005, 4(12): 1920-1932.
18	TIEDT R, KING F J, STAMM C, et al. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors[J]. Cell Rep, 2023, 42(4): 112297.
19	WANG H Q, CUI B M, YAN H Y, et al. Targeting 7-dehydrocholesterol reductase against EV-A71 replication by upregulating interferon response[J]. Antivir Res, 2023, 209: 105497.
20	RUAN J Y, ZHANG P, ZHANG Q Q, et al. Colorectal cancer inhibitory properties of polysaccharides and their molecular mechanisms: a review[J]. Int J Biol Macromol, 2023, 238: 124165.
21	YAN X L, ZHENG W W, GENG S, et al. Cytokine receptor-like factor 3 negatively regulates antiviral immunity by promoting the degradation of TBK1 in teleost fish[J]. J Virol, 2023, 97(1): e0179222.
22	YANG S, JIN S H, XIAN H F, et al. Metabolic enzyme UAP1 mediates IRF3 pyrophosphorylation to facilitate innate immune response[J]. Mol Cell, 2023, 83(2): 298-313.e8.
23	JING T, ZHAO B Y, XU P B, et al. The structural basis of IRF-3 activation upon phosphorylation[J]. J Immunol, 2020, 205(7): 1886-1896.
24	KUHL N, LINDER A, PHILIPP N, et al. STING agonism turns human T cells into interferon-producing cells but impedes their functionality[J]. EMBO Rep, 2023, 24(3): e55536.
25	YUM S, LI M H, FANG Y, et al. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections[J]. Proc Natl Acad Sci USA, 2021, 118(14): e2100225118.
26	GAO Q Z, ZHOU R, MENG Y, et al. Long noncoding RNA CMPK2 promotes colorectal cancer progression by activating the FUBP3-c-Myc axis[J]. Oncogene, 2020, 39(19): 3926-3938.
27	YANG L Q, HU H Y, HAN Y, et al. CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription[J]. Cancer Gene Ther, 2022, 29(12): 1895-1907.
28	YANG J Q, ZHANG Q, WANG J L, et al. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy[J]. EBioMedicine, 2022, 78: 103958.
29	XU S S, LIU Y C, MA H S, et al. A novel signature integrated of immunoglobulin, glycosylation and anti-viral genes to predict prognosis for breast cancer[J]. Front Genet, 2022, 13: 834731.
30	YANG C S, JIVIDEN K, KAMATA T, et al. Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly[J]. Nat Commun, 2021, 12(1): 2705.
31	WANG L D, SUN X D, HE J N, et al. Functions and molecular mechanisms of deltex family ubiquitin E3 ligases in development and disease[J]. Front Cell Dev Biol, 2021, 9: 706997.
32	BOLIS M, PARONI G, FRATELLI M, et al. All-trans retinoic acid stimulates viral mimicry, interferon responses and antigen presentation in breast-cancer cells[J]. Cancers, 2020, 12(5): 1169.
33	AHMED S F, BUETOW L, GABRIELSEN M, et al. DELTEX2 C-terminal domain recognizes and recruits ADP-ribosylated proteins for ubiquitination[J]. Sci Adv, 2020, 6(34): eabc0629.
34	LO P K, YAO Y, LEE J S, et al. LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer[J]. eLife, 2018, 7: e31334.
35	ZHOU Y J, LI G L, WANG J Y, et al. PD-L1: expression regulation[J]. Blood Sci, 2023, 5(2): 77-91.
36	ROTMAN J, DEN OTTER L A S, BLEEKER M C G, et al. PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential[J]. Front Immunol, 2020, 11: 596825.
37	WU Y L, CHEN W Y, XU Z P, et al. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition[J]. Front Immunol, 2019, 10: 2022.
38	SHEN X, ZHAO B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis[J]. BMJ, 2018, 362: k3529.
39	WANG X, TENG F F, KONG L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J]. Onco Targets Ther, 2016, 9: 5023-5039.

[1]	YU Kai, SHUAI Zhewei, HUANG Hongjun, LUO Yan. Research progress on the role and mechanisms of microglia in inflammatory diseases of central nervous system [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(5): 630-638.
[2]	LI Linying, CAI Xiaodong, TONG Ran, YANG Chen, WANG Zhiming, HE Xiaoyu, MA Ziyue, ZHANG Feng, LI Lingjie, ZHOU Junmei. Analysis of transcriptome and chromatin accessibility changes during the differentiation of human embryonic stem cells into neural progenitor cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(4): 387-403.
[3]	LUO Wen, LÜ Mingjun, ZHANG Zhen, ZHANG Xue, YAO Zhirong. Research progress on the dual effects of autophagy in cutaneous melanoma and its role in drug resistance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(2): 233-240.
[4]	TANG Junqian, LI Benshang. Advances in the treatment of pediatric B-cell acute lymphoblastic leukemia with high-risk cytogenetics [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(10): 1390-1399.
[5]	ZHANG Yong, LI Weihong, CHENG Zhipeng, WANG bin, WANG Siheng, WANG Yubin. Research status of receptor-interacting protein kinase 1 in regulating cancer progression and immune response [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 788-794.
[6]	DING Yanling, LI Jie, YUAN Jun, LI Yan. Research progress in targeted therapies of chronic lymphocytic leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 264-270.
[7]	TANG Sijie, MI Jianqing. Clinical advances in antibody-drug conjugates for hematological malignancies [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(12): 1607-1614.
[8]	FANG Xinyue, SHI Lan, XIA Siyi, WANG Jiaxuan, WU Yingli, HE Kejun. Research progress in Menin-MLL interaction and its inhibitors in MLL-rearranged leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(10): 1287-1298.
[9]	ZHOU Wanzhen, TENG Yincheng. Research progress of the role of non-canonical Wnt signaling pathway in ovarian cancer and its potential therapeutic implications [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1056-1063.
[10]	WEI Lanyi, XUE Xiaochuan, CHEN Junjun, YANG Quanjun, WANG Mengyue, HAN Yonglong. Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 624-630.
[11]	XU Yinglian, TIAN Jing, ZHANG Xiang, ZHAO Shunying. Research progress in the roles of airway epithelial cells in the pathogenesis of asthma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 619-623.
[12]	MEI Yanqing, HAN Yujie, WENG Wenyun, ZHANG Lei, TANG Yujie. In vitro therapeutic effects and molecular mechanisms of targeted inhibition of CDK12/13 in high-grade gliomas [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 545-559.
[13]	LIU Tiexin, LIN Junqing, ZHENG Xianyou. Research progress of subcellular structure-targeted therapy in spinal cord injury [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 230-236.
[14]	QIN Yahan, ZHANG Ke, ZHANG Mengyu, SHEN Jie, PENG Meiyu. Research progress of MDSCs-targeted immunotherapy for pancreatic cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1317-1323.
[15]	HAN Yongqi, HAN Da, XIA Qian, JI Dingkun, TAN Weihong. Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1176-1181.